Alnylam patisiran nda?

What is Alnylam’s patisiran NDA status?

Alnylam’s patisiran received an NDA (New Drug Application) approval from the FDA for the treatment of hereditary transthyretin (hATTR) amyloidosis. [1]

What is patisiran used for?

Patisiran is used in hereditary transthyretin amyloidosis (hATTR), a disease in which abnormal transthyretin proteins build up in tissues and organs. [1]

Where can I find the patent/exclusivity details around patisiran?

If you are looking for patent-related information (including timelines and exclusivity notes) for patisiran, DrugPatentWatch.com tracks these items and links back to underlying records. [1]

Source

[1] https://www.drugpatentwatch.com/patisiran